Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

214
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
214
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

287
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
287
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

281
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
281
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

175
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
175
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

382
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
382
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

72
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
72

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individualized Therapy Guided by Drug Susceptibility Testing for Multidrug-Resistant Tuberculosis.

Open forum infectious diseases·2026
Same author

Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing.

Nature communications·2026
Same author

Global burden of drug-resistant tuberculosis in children: A systematic analysis for the Global Burden of Disease Study.

The European respiratory journal·2026
Same author

Genomic characterization of the emerging multidrug-resistant <i>Klebsiella pneumoniae</i> ST6668 clone in northern Italy, 2020-2025.

Microbiology spectrum·2026
Same author

Rising bedaquiline resistance: exploring potential causes and next steps.

The European respiratory journal·2026
Same author

Effect of anti-tuberculosis drugs on the pharmacokinetics and pharmacodynamics of novel antidiabetic drugs: A scoping review.

Pulmonology·2026
Same journal

A hypermetabolic pulmonary lesion in a patient with breast cancer.

Breathe (Sheffield, England)·2026
Same journal

Rigid bronchoscopy is the gold standard management of inhaled foreign bodies in children: myth or maxim?

Breathe (Sheffield, England)·2026
Same journal

The price of immune awakening: bridging knowledge gaps in checkpoint inhibitor-related pneumonitis in lung cancer.

Breathe (Sheffield, England)·2026
Same journal

Where are we with biomarkers in paediatric asthma in 2026?

Breathe (Sheffield, England)·2026
Same journal

Recurrent invasive fungal infection with locally advanced thymoma: diagnostic challenges in complex mediastinal disease.

Breathe (Sheffield, England)·2026
Same journal

Elevated <i>D</i> <sub>LCO</sub> and pulmonary function evolution during treatment in a patient with hyperleukocytosis and leukostasis.

Breathe (Sheffield, England)·2026
See all related articles

Related Experiment Video

Updated: Jul 26, 2025

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.9K

Tuberculosis: current challenges and beyond.

Raquel Villar-Hernández1,2,3, Arash Ghodousi4,3, Olha Konstantynovska5,3

  • 1Institut d'Investigació Germans Trias i Pujol, Barcelona, Spain.

Breathe (Sheffield, England)
|June 19, 2023
PubMed
Summary
This summary is machine-generated.

Tuberculosis (TB) remains a global health crisis despite being preventable and curable. Urgent, multi-sectoral action and research investment are crucial to combat TB and overcome setbacks from pandemics and conflicts.

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K

Related Experiment Videos

Last Updated: Jul 26, 2025

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.9K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K

Area of Science:

  • Global Health
  • Infectious Diseases
  • Public Health Policy

Background:

  • Tuberculosis (TB) is a major global health threat and the second leading cause of infectious disease death.
  • Progress in reducing TB incidence and mortality has been slow and hampered by the COVID-19 pandemic.
  • Recent global conflicts exacerbate the challenge of controlling the TB burden.

Purpose of the Study:

  • To highlight the persistent global threat of tuberculosis.
  • To underscore the impact of recent global events on TB control efforts.
  • To advocate for intensified and innovative strategies to end TB.

Main Methods:

  • This study is a review and analysis of the current global TB situation.
  • It synthesizes data on TB incidence, mortality, and progress towards End TB Strategy targets.
  • It examines the impact of external factors like pandemics and conflicts on TB control.

Main Results:

  • Global efforts have led to slow decreases in TB incidence and mortality.
  • The COVID-19 pandemic has negatively impacted TB control programs.
  • Ongoing conflicts pose a further threat to TB reduction efforts.
  • Most End TB Strategy targets are currently off track.

Conclusions:

  • Ending tuberculosis requires urgent, global, and multi-sectoral commitment.
  • Significant investments in research and innovation are essential.
  • Equitable and rapid implementation of new strategies is critical to regain momentum.